PBAC's latest decision on Faricimab: Recommended with restriction (2025). Considered for Treatment of macular oedema secondary to retinal vein occlusion (RVO), including both branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
4
first 2022
PBS spend
$125M
116,842 scripts · 2024
Eligible population
Adults with visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO) with best corrected visual acuity between 73 and 20 letters, or central retinal vein occlusion (CRVO) with best corrected visual acuity between 73 and 24 letters, diagnosed by optical coherence tomography or fluorescein angiography.
Therapy area
Ophthalmology
Line of therapy
First-line
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
lowest cost PBS-listed anti-VEGF treatment (faricimab vial, aflibercept, or ranibizumab)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as this is a formulation change (pre-filled syringe vs vial) of an already-listed drug.
PBS expenditure
The Australian government paid $125M in PBS benefits for Faricimab in 2024 across 116,842 scripts, at $1,067 per script.
Submission history
May 2022: Recommended with restriction · Authority Required
May 2022: Recommended with restriction · Authority Required
Jul 2024: Recommended with restriction · Authority Required
Mar 2025: Recommended with restriction · Authority Required